Evaluation of Safety and Parameters of Application Technique

This study has been completed.
Information provided by:
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
First received: January 19, 2012
Last updated: January 24, 2012
Last verified: January 2012
This study is conducted in Europe. The aim of the study is to monitor patients changing therapy from syringe to insulin delivery system as prescribed by the treating physician in Slovakia.

Condition Intervention
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Delivery Systems
Other: No treatment given

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Monitoring of Expected Parameters of the Application Technique and Safety of the Therapy

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Number of insulin applications (punctures) [ Designated as safety issue: No ]
  • Reasons leading to change of the therapy [ Designated as safety issue: No ]
  • Patient satisfaction with NovoPen® 4 insulin delivery system [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adverse reactions [ Designated as safety issue: No ]
  • Hypoglycaemia [ Designated as safety issue: No ]

Enrollment: 4819
Study Start Date: October 2006
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
NovoPen® 4 Other: No treatment given
Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with type 1 diabetes or type 2 diabetes mellitus treated with insulin having changed administration of inulin from syringe to a Novo Nordisk insulin delivery system

Inclusion Criteria:

  • Diabetes mellitus (type 1 or type 2)
  • Treated with insulin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01516242

Bratislava, Slovakia, 811 05
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Jozef Lacka, Csc Novo Nordisk Slovakia s.r.o.
  More Information

Additional Information:
Responsible Party: Public Access to Clinical Trials, Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01516242     History of Changes
Other Study ID Numbers: MS236-1926 
Study First Received: January 19, 2012
Last Updated: January 24, 2012
Health Authority: Slovakia: State Institute for Drug Control

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on April 27, 2016